We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-13.34%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.15B
AUM Growth
-$354M
Cap. Flow
+$252M
Cap. Flow %
11.69%
Top 10 Hldgs %
47.71%
Holding
76
New
9
Increased
16
Reduced
38
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$76.6M
2
XLRN
Acceleron Pharma
XLRN
+$64.1M
3
AGEN
Agenus
AGEN
+$39M
4
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$30.8M
5
BEAM icon
Beam Therapeutics
BEAM
+$17.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$63.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$19.5M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$258M 11.98%
+1,000,000
New +$305M
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$137M 6.34%
3,056,797
-339,853
-10% -$18M
PRNB
3
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$125M 5.79%
2,100,000
+109,078
+5% +$6.36M
BBIO icon
4
BridgeBio Pharma
BBIO
$16.4B
$85.5M 3.98%
2,950,000
+437,135
+17% +$13.6M
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
$81.4M 3.78%
2,025,000
-875,000
-30% -$37.2M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$74.1M 3.45%
+825,000
New +$64.1M
RETA
7
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$70.3M 3.27%
487,206
-329,194
-40% -$63.6M
VIE
8
DELISTED
Viela Bio, Inc. Common Stock
VIE
$67M 3.11%
1,762,500
+265,000
+18% +$10.3M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$65.3M 3.04%
850,000
-432,392
-34% -$38.8M
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$64.1M 2.98%
2,040,021
-259,979
-11% -$9.04M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$60.7M 2.82%
2,266,108
-433,892
-16% -$15.4M
RVMD icon
12
Revolution Medicines
RVMD
$38.5B
$60.6M 2.82%
+2,767,078
New +$76.6M
EIDX
13
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$53.9M 2.5%
1,100,000
+604,308
+122% +$30.8M
YMAB
14
DELISTED
Y-mAbs Therapeutics
YMAB
$45.2M 2.1%
1,732,200
+129,824
+8% +$3.77M
ASND icon
15
CALL
Ascendis Pharma A/S
ASND
$16.5B
$39.4M 1.83%
350,000
+100,000
+40% +$13M
STOK icon
16
Stoke Therapeutics
STOK
$1.84B
$39.2M 1.82%
1,709,765
-78,878
-4% -$1.95M
MRTX
17
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$38.4M 1.79%
500,000
– –
RETA
18
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$36.1M 1.68%
250,000
– –
OMER icon
19
Omeros
OMER
$845M
$33.7M 1.57%
2,523,700
+998,700
+65% +$13.3M
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$32.8M 1.52%
700,000
– –
AGEN
21
Agenus
AGEN
$276M
$29.8M 1.39%
+620,290
New +$39M
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$29.8M 1.38%
875,551
-124,449
-12% -$5.69M
AXSM icon
23
Axsome Therapeutics
AXSM
$11.7B
$29.4M 1.37%
500,000
-100,000
-17% -$8.15M
ASND icon
24
Ascendis Pharma A/S
ASND
$16.5B
$28.2M 1.31%
250,000
-150,000
-38% -$19.5M
NXTC icon
25
NextCure
NXTC
$20.4M
$27.6M 1.28%
61,950
-21,383
-26% -$11.4M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Cormorant Asset Management held 76 positions worth $2.15B, down 14% from $2.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $252M of net new capital in Q1 2020, opening 9 new positions and adding to 16 existing holdings. Its largest new stake was Revolution Medicines: 2,767,078 shares worth $60.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $63.6M trimmed.

  • Cormorant Asset Management's largest Q1 2020 buy was Revolution Medicines: 2,767,078 shares worth $60.6M.
  • Cormorant Asset Management added most to Eidos Therapeutics, Inc. Common Stock in Q1 2020, an estimated $30.8M increase.
  • Cormorant Asset Management's biggest Q1 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $63.6M.
  • Cormorant Asset Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $2.15B portfolio in Q1 2020.
  • Cormorant Asset Management opened 9 new positions and closed 3 in Q1 2020.
  • Cormorant Asset Management's portfolio value fell 14% quarter-over-quarter to $2.15B.

Based on Cormorant Asset Management's 13F filing for Q1 2020, filed 15 May 2020.